Literature DB >> 7007589

Immunobiology of primary intracranial tumors. Part 5: Correlation of a lymphocyte index and clinical status.

W H Brooks, R B Latta, M S Mahaley, T L Roszman, L Dudka, C Skaggs.   

Abstract

Long-term assessment of general host immunocompetence of patients with primary malignant brain tumors indicates that although isolated determinations of nonspecific responsiveness are not clinically useful, sequential analyses utilizing a linear combination of in vitro lymphocyte probes are capable of predicting tumor recurrence prior to clinical deterioration.

Entities:  

Mesh：

Year:  1981        PMID： 7007589     DOI： 10.3171/jns.1981.54.3.0331

Source DB:  PubMed          Journal:  J Neurosurg        ISSN： 0022-3085            Impact factor:   5.115


  21 in total

1.  TGF-beta2 inhibition augments the effect of tumor vaccine and improves the survival of animals with pre-established brain tumors.

Authors:  Yang Liu; Qing Wang; B K Kleinschmidt-DeMasters; Alex Franzusoff; Ka-yun Ng; Kevin O Lillehei
Journal:  J Neurooncol       Date:  2006-08-29       Impact factor: 4.130

Review 2.  Serial immune function testing to predict clinical disease relapse in patients with solid tumors.

Authors:  D P Braun; J E Harris
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

Review 3.  Combining cytotoxic and immune-mediated gene therapy to treat brain tumors.

Authors:  James F Curtin; Gwendalyn D King; Marianela Candolfi; Remy B Greeno; Kurt M Kroeger; Pedro R Lowenstein; Maria G Castro
Journal:  Curr Top Med Chem       Date:  2005       Impact factor: 3.295

4.  Lymphocyte subsets in patients with brain tumors.

Authors:  M Uegaki; S Kobayashi; S Kuramoto; M M Yokoyama
Journal:  J Neurooncol       Date:  1988       Impact factor: 4.130

5.  Cellular immunity and complement levels in hosts with brain tumours.

Authors:  M Matsutani; T Suzuki; T Hori; H Terao; K Takakura; K Nishioka
Journal:  Neurosurg Rev       Date:  1984       Impact factor: 3.042

6.  Immunologic status in children with brain tumors and the effect of therapy.

Authors:  R Kebudi; I Ayan; E Darendeliler; L Ağaoğlu; S Ekmekçioğlu; T Yağci; S Pişkin; N Bilge
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

7.  Particular features of cell-mediated immunity in patients with anaplastic gliomas. A comparison with kidney and bladder cancer patients.

Authors:  F Servadei; R Parente; M Bucci; E Beltrandi; F Tognetti; G Gaist
Journal:  J Neurooncol       Date:  1983       Impact factor: 4.130

8.  Specific adoptive immunotherapy of malignant glioma with long-term cytotoxic T lymphocyte line expanded in T-cell growth factor. Experimental study and future prospects.

Authors:  T Yamasaki; H Handa; J Yamashita; Y Watanabe; Y Namba; M Hanaoka
Journal:  Neurosurg Rev       Date:  1984       Impact factor: 3.042

9.  Suppression of high affinity IL-2 receptors on mitogen activated lymphocytes by glioma-derived suppressor factor.

Authors:  L H Elliott; W H Brooks; T L Roszman
Journal:  J Neurooncol       Date:  1992-09       Impact factor: 4.130

10.  Immunological monitoring of patients affected by anaplastic glioma concerning in effects of surgery, radio-, and chemotherapy. A preliminary report.

Authors:  F Servadei; R Parente; F Spagnolli; G Gaist; R Padovani; M Bucci; L Steiner
Journal:  Acta Neurochir (Wien)       Date:  1982       Impact factor: 2.216
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.